Effects of N-n-butyl haloperidol iodide (F2) on Egr-1 mRNA and protein expression after myocardial ischemia-reperfusion

Abstract

Abstract: AIM: To investigate the effects of N-nbutyl haloperidol iodide (F₂) on Egr-1 mRNA and protein expression in the model of rats with myocardial ischemiareperfusion. METHODS: The myocardial ischemiareperfusion injury animal model was established by occluding rat's left anterior descending branch of coronary artery for 60min and later opening the ligation to reperfusion for 180 min in vivo.F₂ were administered by intravenous injection before the onset of ischemia for 5 min.The changes of hemodynamics were recorded during the experiment, and then the ischemia tissue was extract.The inflammation was observed by tissue section.The Egr-1 gene transcription and protein expression were detected by RT-PCR and Western-blot, respectively.RESULTS: F₂ reduced the levels of Egr-1 mRNA and protein, relieve inflammation and ameliorate the hemodynamics of ischemia-reperfusion injured myocardium.CONCLUSION: F₂ can relieve inflammatory injury and protect myocardial function in rats with myocardial ischemia-reperfusion, and the mechanism may be related to attenuating the transcription and expression of Egr-1.

Key words: N-n-butyl haloperidol iodide, Egr-1, myocardial ischemia-reperfusion injury, hemodynamics, inflammation, neutrophil, transcription factor

CLC Number:

R966

TANG Zhao, SHI Gang-Gang, ZHANG Yan-Mei, YIN Jun, ZHOU Yan-Qiong, HUANG Zhan-Qin, GAO Fen-Fei. Effects of N-n-butyl haloperidol iodide (F2) on Egr-1 mRNA and protein expression after myocardial ischemia-reperfusion[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(12): 1343-1348.

References

1 Yan SF, Fujita T, Lu J, Okada K, Shan ZY, Mackman N, et al.Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress[J].Nat Med, 2000;6(12):1355-61
2 Okada M, Fujita T, Sakaguchi T, Olson KE, Collins T, Stern DM, et al.Extinguishing Egr-1-dependent inflammatory and thrombotic cascades after lung transplantation[J].FASEB J, 2001;15(14):2757-9
3 Okada M, Wang CY, Hwang DW, Sakaguchi T, Olson KE, Yoshikawa Y, et al.Transcriptional control of cardiac allograft vasculopathy by early growth response gene-1 (Egr-1) [J]. Circ Res, 2002;91(2):135-42
4 Huang ZQ, Shi GG, Chen CY, Li WQ.Protective effect of quaternary ammonium salt derivative (F2) of haloperidol on iodide on rat myocardial ischemia and reperfusion injury and Ltype calcium current[J].Acta Pharmacol Sin, 2003;24(8): 757-63
5 庄学煊, 陈少刚, 黄展勤, 石刚刚.氟哌啶醇季铵盐衍生物对大鼠急性心肌缺血的保护作用[J].汕头大学医学院学报, 2001;14(3):172-4
6 高分飞, 石刚刚, 郑锦鸿, 李长潮, 庄学煊, 刘幸平, 等.碘化正丁基氟哌啶醇对兔心肌缺血再灌注损伤血流动力学和心肌组织中酶的影响[J].中国药理学通报, 2003;19(5):559-62
7 周燕琼, 石刚刚, 高分飞, 刘幸平, 樊化平, 黄展勤.碘化正丁基氟哌啶醇对大鼠心肌缺血再灌注损伤血流动力学的影响[J].中国药理学通报, 2004;20(4):449-52
8 Bochkov VN, Mechtcheriakova D, Lucerna M, Huber J, Malli R, Graier WF, et al.Oxidized phospholipids stimulate tissue factor expression in human endothelial cells via activation of ERK EGR-1 and Ca²⁺ NFAT[J].Blood, 2002;99(1):199-206
9 Arai M, Yoguchi A, Takizawa T, Yokoyama T, Kanda T, Kurabayashi M, et al.Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca²⁺-ATPase gene transcription [J].Circ Res, 2000;86(1):8-14
10 Khachigian LM, Lindner V, Williams AJ, Collins T.Egr-1-induced endothelial gene expression:a common theme in vascular injury[J].Science, 1996;271:1427-31
11 Bahouth SW, Beauchamp MJ, Vu KN.Reciprocal Regulation of β1-adrenergic receptor gene transcription by Sp1 and early growth response gene 1:induction of EGR-1 inhibits the expression of the β1-adrenergic receptor gene[J].Mol Pharmacol, 2002;61(2):379-90

[1]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.
[2]	ZHAO Lingzhi, HE Yanjun, XIE Jianqin, YOU Chongge. Research progress on therapeutic role of recombinant human soluble thrombomodulin in atherosclerosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 832-840.
[3]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[4]	LIU Jiajun, QUE Zujun, TIAN Jianhui. Comparative study on the ability of active ingredients in Jinfukang to decrease neutrophils recruiting by lung cancer circulating tumor cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 1-9.
[5]	LIANG Hongyu, ZHANG Hailin, YIN Huanxin, CHEN Fan, LU Junlin, ZHU Caihong, HU Wei, ZHOU Renpeng. Effects of 2-APB in skin wound healing in mice through down-regulation of TRPM7 [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 747-753.
[6]	MAO Shuying, JIN Wei, FU Sisi, LIU Keanqi, ZHOU Zhihao, WANG Guangji, LIANG Yan. Oral lienal peptides improve ammonia-induced coughing and inflammation in mice [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 601-607.
[7]	JIN Yiyi, ZHOU Keting, YANG Chengcheng, XU Ping, ZHU Suyan. Osthole attenuates diabetes-induced renal injury by regulating NF-κB and p38/MAPK pathway mediated inflammatory responses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 622-631.
[8]	CHANG Shufu . Progress of medical treatment of coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 405-408.
[9]	WEI Jifang, YUE Hongmei, LIU Nanyu, SONG Peipei, XIE Yingying, WANG Jiaqi, WEI Yaqian. Research progress on the relationship between thyroid hormone and idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 307-313.
[10]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
[11]	YAN Lei, JIANG Haibin, NAFEISHA Paerhati, REZIWANGULI Yikemu, GENG Boyu, MAIERHABA Maimaitiaili. Effects of different doses of dexmedetomidine on non-cardiac surgery stress and postoperative sleep in patients with coronary heart disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1340-1346.
[12]	CHEN Yu, GU Bing, LI Huanan. Modulating gut miocrobiota: a new strategy in the treatment of gout [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1307-1314.
[13]	CHEN Yugang, TU Yanqiong, WANG Congqing, CHEN Juan, ZHANG Bohong. Network pharmacology and molecular docking to discuss the mechanism of Jinhutongdan prescription in the treatment of cholelithiasis and experimental verification [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1090-1098.
[14]	LI Ying, YAO Wei, WANG Meng, YU Zhihong, GONG Yuanqi, LAN Haibing, QI Xiefei. Experimental study of irisin alleviates house dust mite-induced airway epithelial cells inflammation and apoptosis via the NF-κB and JNK signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(10): 1106-1112.
[15]	WU Lin, HAO Yingxiang, ZHANG Lei, ZHANG Tianxue, GAO Mingjing, LENG Yufang. Paricalcitol attenuates intestinal ischemia-reperfusion injury in mice through HMGB1/TLR4/NF-κB signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 1-7.